Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
British Journal of Cancer
|
August 18, 2011
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines
E Arriola, I Cañadas, M Arumí-Uría, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 29, 2008
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines
G J Weiss, L T Bemis, E Nakajima, et al.
British Journal of Cancer
|
November 17, 2005
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
F Cappuzzo, L Toschi, I Domenichini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2007
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
F R Hirsch, M Varella-Garcia, F Cappuzzo, et al.
British Journal of Cancer
|
July 28, 2012
βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer
D C Christoph, S Kasper, T C Gauler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2006
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
F Cappuzzo, L Toschi, G Tallini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2019
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y Wang, T Jiang, Z Qin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
T Brodowicz, T Ciuleanu, J Crawford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
P D Bonomi, D Gandara, F R Hirsch, et al.
ESMO Open
|
February 12, 2022
Consensus for HER2 alterations testing in non-small-cell lung cancer
S Ren, J Wang, J Ying, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
British Journal of Cancer
|
August 18, 2011
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines
E Arriola, I Cañadas, M Arumí-Uría, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 29, 2008
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines
G J Weiss, L T Bemis, E Nakajima, et al.
British Journal of Cancer
|
November 17, 2005
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
F Cappuzzo, L Toschi, I Domenichini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2007
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
F R Hirsch, M Varella-Garcia, F Cappuzzo, et al.
British Journal of Cancer
|
July 28, 2012
βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer
D C Christoph, S Kasper, T C Gauler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2006
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib
F Cappuzzo, L Toschi, G Tallini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2019
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
Y Wang, T Jiang, Z Qin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 24, 2011
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
T Brodowicz, T Ciuleanu, J Crawford, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer
P D Bonomi, D Gandara, F R Hirsch, et al.
ESMO Open
|
February 12, 2022
Consensus for HER2 alterations testing in non-small-cell lung cancer
S Ren, J Wang, J Ying, et al.
Page
of 8